Stem Cell Therapy for Spinal Cord Injury: Lessons from Japan`s Experiment in Regulatory Deregulation
Stem cell-based therapies for spinal cord injury (SCI) have generated substantial global interest; however, no regenerative treatment has yet demonstrated sufficient efficacy to achieve full regulatory approval in major jurisdictions. In Japan, an expedited regulatory framework enabled the conditional approval of Stemirac, an autologous mesenchymal stem cell therapy for SCI, based on limited and uncontrolled clinical evidence. This Perspective examines the scientific, methodological, and ethical implications of that decision. Focusing on trial design, outcome assessment, extensive public and media attention during the confirmatory trial period, and downstream societal consequences, we explore how premature commercialization under public reimbursement may compromise scientific rigor and erode public trust.
Source: ScienceDirect
